You have 9 free searches left this month | for more free features.

Condition

Head and Neck Squamous Cell Carcinoma (1)

Metastatic Melanoma (1)

Non-Small Cell Lung Cancer (1)

Non-alcoholic Steatohepatitis (NASH) (1)

Pharmacokinetics (1)

Safety and Tolerability (1)

Overall Status

Recruiting (2)

Completed (1)

Not yet recruiting (1)

Withdrawn (1)

Sign in for free

Phase

phase 1 (2)

phase 1/phase 2 (2)

phase 2 (1)

Sponsor

Galecto Biotech AB (4)

Providence Health & Services (1)

Collaborator

Covance (1)

Galecto Biotech AB (1)

Hoffmann-La Roche (1)

Linical Europe GmbH (1)

Providence Cancer Center (1)

Providence Cancer Center, Earle A. Chiles Research Institute (1)

QPS Holdings LLC (1)

Intervention

gb1211 (5)

placebo (4)

atezolizumab (1)

pembrolizumab (1)

Study Documents

Intervention Type

drug (5)

Funder Type

Industry (4)

Other (1)

Study Type

Interventional (5)

gb1211

Showing 1 - 5 of 5

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Pharmacokinetics Trial in Groningen (GB1211)

Recruiting

Pharmacokinetics

GB1211

Groningen, Netherlands

QPS Netherlands BV

Feb 16, 2023

Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Portland (GB1211, Pembrolizumab, Placebo)

Not yet recruiting

Metastatic Melanoma
Head and Neck Squamous Cell Carcinoma

GB1211
+2 more

Portland, Oregon

Providence Portland Medical Center

Jun 19, 2023

NSCLC Trial in France, Spain (GB1211, Placebo, Atezolizumab)

Recruiting

Non-Small Cell Lung Cancer

GB1211
+2 more

Dijon, France
+7 more

Sep 30, 2022

Safety and Tolerability Trial in Leeds (GB1211, Placebo)

Completed

Safety and Tolerability

GB1211
Placebo

Leeds, United Kingdom

(For Parts A and B) Covance Clinical Research Unit Ltd

Feb 25, 2021

Non-alcoholic Steatohepatitis (NASH) Trial (GB1211, Placebo)

Withdrawn

Non-alcoholic Steatohepatitis (NASH)

GB1211
Placebo

(no location specified)

Feb 2, 2021